OSE Immunotherapeutics SA (OSE) To Present Combi-TED Phase 2 Topline Results at ESMO 2026

OSE Immunotherapeutics SA said topline results from the Phase 2 Combi-TED trial of Tedopi in metastatic NSCLC were selected for oral presentation at ESMO 2026. The study tested Tedopi plus nivolumab or docetaxel vs docetaxel alone as second-line therapy.Material DetailsContext by AI AnalystThis is…